biotech
biotech Articles
Galena Biopharma, Inc. (NASDAQ: GALE) is absolutely crashing on Wednesday after the company released further information regarding its Breast Cancer clinical trial. The company announced the...
Published:
Last Updated:
Tesaro, Inc. (NASDAQ: TSRO) is watching its shares make a significant gain on Wednesday after the company released positive late-stage trial results. The company announced that its Phase 3 NOVA trial...
Published:
Last Updated:
Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health care if...
Published:
Last Updated:
inVentiv Group Holdings filed an amended Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were mentioned in this filing,...
Published:
Last Updated:
Regulus Therapeutics Inc. (NASDAQ: RGLS) saw its shares cut in half early Tuesday morning following news of a clinical hold from the U.S. Food and Drug Administration (FDA). The company announced it...
Published:
Last Updated:
The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After all, a cure or...
Published:
Last Updated:
Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked...
Published:
Last Updated:
Nymox Pharmaceutical shares made solid headway in Wednesday’s session on positive results from a cancer trial.
Published:
Last Updated:
Global Blood Therapeutics shares saw a handy gain in the premarket on Tuesday, despite the company pricing its secondary offering below its previous price level.
Published:
Last Updated:
These four biotech companies not only have data that could prove to be huge, but they have been absolutely hammered over the past year, offering aggressive accounts the best entry points in some time.
Published:
Last Updated:
Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of preliminary data from its HIV treatment. After the stock dropped about...
Published:
Last Updated:
Selecta Biosciences intends to price more than 4 million shares in the range of $14 to $16 per share for an initial public offering valued up to more than $78 million.
Published:
Last Updated:
Shares of Fate Therapeutics saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA) approval.
Published:
Last Updated:
Whole Foods, Synchrony Financial and others led the charge in last week's market pullback and absolutely crushed shareholders.
Published:
Last Updated:
Audentes Therapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated: